Stereo Drugs Private Limited, a active private limited company, was established on 06 June 2008 in Rangareddy, Telangana, India. Engaging in pharmaceutical retailers & distributors within the manufacturing sector, it holds CIN: U24233TG2008PTC059539. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹3.00 Cr and a paid-up capital of ₹3.00 Cr.
It upholds a compliant status. Its leadership includes Prathima Arveti (Director), Akkisani (Managing Director). Past directors included Anand Srinivas Katta, Kinthada Vijaya Lakshmi, Kinthada Suryanarayana. It holds no open charges and ₹17.06 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Plot No.165/P, Aparna Palm Groves, Ground Floor, Phase-1, Kompally, Medchal Dist, Telangana, Rangareddy, Telangana, 500100.
U24233TG2008PTC059539
059539
06 June 2008
₹3.00 Cr
₹3.00 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Stereo Drugs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Prathima Arveti | Director | 17 Aug 2023 | Current |
| Akkisani | Managing Director | 01 Dec 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 22 Aug 2023 | Past |
| Pramod Abcsdd | Director | 01 Dec 2022 | Past |
| Pramod Abcsdd | Managing Director | 10 Jun 2022 | Past |
| Pramod Abcsdd | Director | 31 Jul 2014 | Past |
| Pramod Abcsdd | Director | 26 Mar 2009 | Past |
| Pramod Abcsdd | Director | 18 Dec 2009 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Stereo Drugs Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 41.27% decrease. The company also saw a substantial improvement in profitability, with a 147.77% increase in profit. The company's net worth moved up by a moderate rise of 0.39%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Stereo Drugs had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹170,567,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Feb 2014 | Axis Bank Limited | ₹0.54 M | Satisfied |
| 31 Oct 2013 | Axis Bank Limited | ₹11.86 Cr | Satisfied |
| 22 Aug 2011 | Corporation Bank | ₹5.14 Cr | Satisfied |
Explore comprehensive loan charge details -
Stereo Drugs has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Stereo Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stereo Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Stereo Drugs Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Stereo Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was recorded as a recent event.
Progress on Prathima Arveti was appointed as a Director was appointed as a Director on 17 Aug 2023 & has been associated with this company since 2 years 4 months . was documented.
Akkisani was appointed as a Managing Director was appointed as a Managing Director on 01 Dec 2022 & has been associated with this company since 3 years 19 days . was recorded as a recent event.
Progress on A charge registered on 31 Oct 2013 via Charge ID 10459599 with Axis Bank Limited was fully satisfied on 05 May 2022. was documented.
A charge registered on 17 Feb 2014 via Charge ID 10483075 with Axis Bank Limited was fully satisfied on 02 May 2022. was recorded as a recent event.
The CIN of Stereo Drugs Private Limited is U24233TG2008PTC059539.
Stereo Drugs Private Limited is headquartered at Plot No.165/P, Aparna Palm Groves, Ground Floor, Phase-1, Kompally, Medchal Dist, Telangana, Rangareddy, Telangana, 500100.
Stereo Drugs Private Limited was incorporated on 06 June 2008.
The current directors of Stereo Drugs Private Limited are
The primary industry of Stereo Drugs Private Limited is Manufacturing.
Stereo Drugs Private Limited is unlisted.
The authorized capital of Stereo Drugs Private Limited is ₹3.00 Cr, and the paid-up capital is ₹3.00 Cr.
The compliance status of Stereo Drugs Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX